by Beth Israel Deaconess Medical Center Graphical Abstract. Credit: Journal of Urology (2023). DOI: 10.1097/JU.0000000000003789Each year, more than a million transrectal biopsies are performed in the United States. The primary technique for diagnosing and monitoring prostate cancer, a transrectal biopsy, entails removing tissue from the prostate gland by inserting a thin needle through the rectal wall....
Tag: <span>Prostate cancer</span>
Focal Therapy for Prostate Cancer: Evidence-Based or Oversold?
Howard Wolinsky In 2013, a prostate-specific antigen (PSA) blood test revealed that Richard LaFrate’s levels had jumped. Previously in a normal range, LaFrate’s PSA was now above 6 ng/mL, indicating an elevated likelihood for prostate cancer. The jazz guitarist from Leesburg, Florida, then 70 years old, underwent a biopsy, which found two Gleason 6 lesions....
Plant-based diet tied to improved sexual health in men treated for prostate cancer
by NYU Langone Health Credit: CC0 Public DomainA diet that limits meat and dairy but is rich in fruits, vegetables, grains, and nuts is linked to less erectile dysfunction, urinary incontinence, and other common side effects seen in prostate cancer patients, a new study shows. Led by researchers at NYU Grossman School of Medicine and Harvard...
Comparing side effects after prostate cancer treatment
At a GlanceMen with cancer confined to the prostate experienced different long-term side effects depending on the type of treatment received.Understanding the pros and cons of different treatments may help men and their health care teams make more informed treatment decisions.Doctor showing something on a clipboard to a senior man.The choice of treatment for prostate...
Long-term follow up pinpoints side effects of treatments for prostate cancer patients
by Vanderbilt University Medical Center Credit: Unsplash/CC0 Public DomainA 10-year follow-up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision-making in terms of treatments and side effects for a diverse population. The CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation for Localized Prostate Cancer) study, coordinated by Vanderbilt University Medical...
Newly developed inhibitor shows potential for prostate cancer
by Albert Ludwigs University of Freiburg Identification of a bi-substrate inhibitor of KMT9. a Chemical structure of compound 1a with predicted binding mode. b MST assay to determine the dissociation constant (Kd) of compound 1a and SAM binding to KMT9. c FTSA for compound 1a binding to KMT9. d Chemical structure of SAM. e FTSA for...
Hard to Drug: Protein Droplets Reveal New Ways to Inhibit Aggressive Form of Prostate Cancer
Many of the most potent human oncoproteins belong to a class of proteins called transcription factors, but designing small molecule drugs that target transcription factors is a major challenge, especially when treating aggressive forms of prostate cancer. An international team of researchers from the Institute for Research in Biomedicine in Barcelona, the Max Planck Institute...
187 new genetic variants linked to prostate cancer found in largest, most diverse study of its kind
by Keck School of Medicine of USC Credit: CC0 Public Domain A globe-spanning scientific team has compiled the most comprehensive list of genetic variants associated with prostate cancer risk—451 in all—through a whole-genome analysis that ranks as the largest and most diverse investigation into prostate cancer genetics yet. The research, led by the USC Center for...
Docetaxel use associated with significant reduction in prostate cancer death in very poor prognostic group
by Brigham and Women’s Hospital Credit: Unsplash/CC0 Public Domain Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis. The question remains as to whether the chemotherapy drug docetaxel, which increases survival in metastatic prostate cancer, can improve the cure rate in these patients. In a new study by investigators from...
Short-Course SBRT: Standard of Care in Prostate Cancer?
Neil Osterweil October 04, 2023 SAN DIEGO — With just five fractions of stereotactic body radiation therapy (SBRT), men with low- or intermediate-risk prostate cancer can have 5-year disease control as good as that provided by conventional external-beam radiation therapy delivered at higher doses in 20-39 fractions, according to new data from the phase 3 randomized PACE-B...